174 related articles for article (PubMed ID: 16390241)
1. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
Kaabipour E; Haupt HM; Stern JB; Kanetsky PA; Podolski VF; Martin AM
Arch Pathol Lab Med; 2006 Jan; 130(1):69-73. PubMed ID: 16390241
[TBL] [Abstract][Full Text] [Related]
2. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma.
Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
Br J Dermatol; 2001 Oct; 145(4):582-9. PubMed ID: 11703284
[TBL] [Abstract][Full Text] [Related]
3. Plasmacytoid dendritic cells in keratoacanthoma and squamous cell carcinoma: A blinded study of CD123 as a diagnostic marker.
Fraga GR; Chow P
J Cutan Pathol; 2020 Jan; 47(1):17-21. PubMed ID: 31449667
[TBL] [Abstract][Full Text] [Related]
4. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients.
Cabibi D; Aragona F; Guarnotta C; Rodolico V; Zerilli M; Belmonte B; Schillaci L; Aragona F
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):239-45. PubMed ID: 21475039
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin.
Krunic AL; Garrod DR; Madani S; Buchanan MD; Clark RE
Br J Cancer; 1998 Apr; 77(8):1275-9. PubMed ID: 9579833
[TBL] [Abstract][Full Text] [Related]
6. Pattern of TGFbeta receptor 1 expression differs between kras-mutated keratoacanthomas and squamous cell carcinomas of the skin.
Berger F; Geddert H; Faller G; Werner M; Dimmler A
Pathol Res Pract; 2014 Sep; 210(9):596-602. PubMed ID: 24954139
[TBL] [Abstract][Full Text] [Related]
7. Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas.
Kuivanen TT; Jeskanen L; Kyllönen L; Impola U; Saarialho-Kere UK
Mod Pathol; 2006 Sep; 19(9):1203-12. PubMed ID: 16699496
[TBL] [Abstract][Full Text] [Related]
8. IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
Soddu S; Di Felice E; Cabras S; Castellanos ME; Atzori L; Faa G; Pilloni L
Eur J Histochem; 2013 Feb; 57(1):e6. PubMed ID: 23549465
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin.
Hodges A; Smoller BR
Mod Pathol; 2002 Nov; 15(11):1121-5. PubMed ID: 12429789
[TBL] [Abstract][Full Text] [Related]
10. Differentiating keratoacanthoma from squamous cell carcinoma-In quest of the holy grail.
Nagarajan P
J Cutan Pathol; 2020 Apr; 47(4):418-420. PubMed ID: 31893469
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Tran TA; Ross JS; Boehm JR; Carlson JA
J Cutan Pathol; 1999 Sep; 26(8):391-7. PubMed ID: 10551411
[TBL] [Abstract][Full Text] [Related]
12. [The value of laminin-322 staining in distinguishing between keratoacanthoma, keratoacanthoma with areas of squamous cell carcinoma, and crateriform squamous cell carcinoma].
Corbalán-Vélez R; Martínez-Barba E; López-Poveda MJ; Vidal-Abarca Gutiérrez I; Ruíz-Maciá JA; Oviedo-Ramirez I; Martínez-Menchón T
Actas Dermosifiliogr; 2012 May; 103(4):308-16. PubMed ID: 22176864
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
14. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma.
Goldenhersh MA; Olsen TG
J Am Acad Dermatol; 1984 Feb; 10(2 Pt 2):372-8. PubMed ID: 6368620
[TBL] [Abstract][Full Text] [Related]
15. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas.
Ho T; Horn T; Finzi E
Arch Dermatol; 1991 Aug; 127(8):1167-71. PubMed ID: 1863074
[TBL] [Abstract][Full Text] [Related]
17. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.
Burnworth B; Arendt S; Muffler S; Steinkraus V; Bröcker EB; Birek C; Hartschuh W; Jauch A; Boukamp P
Eur J Cell Biol; 2007 Dec; 86(11-12):763-80. PubMed ID: 17198740
[TBL] [Abstract][Full Text] [Related]
18. Keratoacanthoma and Keratoacanthoma-Like Squamous Cell Carcinoma: Similar Morphology but Different Pathogenesis.
Watanabe IC; Magalhães RF; de Moraes AM; Stelini RF; Cintra GF; Metze K; Cintra ML
Medicine (Baltimore); 2015 Jun; 94(23):e934. PubMed ID: 26061320
[TBL] [Abstract][Full Text] [Related]
19. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas.
Melendez ND; Smoller BR; Morgan M
Mod Pathol; 2003 Jan; 16(1):8-13. PubMed ID: 12527707
[TBL] [Abstract][Full Text] [Related]
20. The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.
Vasiljević N; Andersson K; Bjelkenkrantz K; Kjellström C; Månsson H; Nilsson E; Landberg G; Dillner J; Forslund O
Int J Cancer; 2009 May; 124(10):2361-6. PubMed ID: 19165861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
